Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of neuraminic acid and neuraminidase inhibitor in chronic heart failure

A technology of chronic heart failure and neuraminic acid, applied in the direction of organic active ingredients, cardiovascular system diseases, medical preparations containing active ingredients, etc., can solve problems such as difficulties in diagnosis and treatment of chronic heart failure, insufficient risk assessment, etc., to achieve The effect of improving efficiency and accuracy, rapid detection means, and huge application value

Active Publication Date: 2019-05-24
TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The present invention aims at the problems of difficulty in diagnosis and treatment of chronic heart failure and insufficient risk assessment in the prior art, and discovers a new biomarker-neuraminic acid, and confirms that neuraminic acid plays a role in the diagnosis and treatment of chronic heart failure. The role of prognostic biomarkers and risk stratification, and its role as a drug target in the prevention, alleviation and / or improvement of chronic heart failure; therefore, the detection of neuraminic acid levels through the kit can be used to predict and assist in the diagnosis of chronic heart failure or Assess the prognosis of chronic heart failure and control the level of neuraminic acid through drugs to carry out more intensive diagnosis and follow-up treatment of the disease and obtain a favorable course of disease, which has great clinical application value

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of neuraminic acid and neuraminidase inhibitor in chronic heart failure
  • Application of neuraminic acid and neuraminidase inhibitor in chronic heart failure
  • Application of neuraminic acid and neuraminidase inhibitor in chronic heart failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] High plasma Neu5Ac levels are associated with severe chronic heart failure

[0037] Study population and study design: From January 2008 to March 2017, two medical centers (Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology in Wuhan City, Hubei Province, and the Second Affiliated Hospital of Hebei Medical University in Shijiazhuang, Hebei Province) were continuously included. Hospitalized patients with chronic heart failure. Inclusion criteria include: age greater than 18 years old, heart failure NYHA classification II-IV. The diagnosis of heart failure is determined on the basis of physical examination, laboratory examination, and echocardiography according to the diagnostic criteria and steps of ACC / AHA. Exclusion criteria include: heart failure caused by severe valvular disease; patients with life-threatening complications such as severe liver dysfunction and renal dysfunction; survival time of patients with maligna...

Embodiment 2

[0042] Increased risk of adverse cardiovascular events in chronic heart failure patients with high plasma Neu5A levels

[0043] Long-term follow-up was carried out on the above-mentioned research population. During the five-year follow-up, only 2 (0.2%) were lost to follow-up. A total of 182 (16.2%) died, of which 149 (13.3%) died of cardiac causes, 3 (0.30%) underwent heart transplantation; 401 (35.8%) were readmitted, of which 297 (26.5%) were of cardiac causes Reasons for hospitalization; 259 people (23.1%) had recurrent heart failure.

[0044] Statistical analysis methods: Kaplan-Meier survival curves were used to display Neu5Ac tertile levels and clinical endpoint events, and log-rank test was used for statistical evaluation of survival curves. Univariate and multivariate Cox proportional hazards regression with 95% confidence intervals were used to estimate hazard ratios (HRs) according to Neu5Ac tertiles. Results were adjusted for traditional risk factors, including ...

Embodiment 3

[0050] Neu5Ac has stronger predictive value than conventional risk factors in patients with chronic heart failure

[0051] There were 498 people in the study population with hsCRP records, and 2 of them were lost to follow-up. This application studies whether the level of Neu5Ac can help predict the prognosis of patients with chronic heart failure, and whether adding Neu5Ac to the statistical model can improve The predictive value of the model. ROC curve analysis showed that AUC was 0.675, revealing that Neu5Ac was a good predictor of cardiac death and heart transplantation. Logistic regression model was used to construct traditional risk factors and hsCRP models with or without Neu5Ac, and receiver operating characteristic (receiver-operating characteristic, ROC) curve, area under (AUC), net reclassification index (net reclassification indexes, NRI ) and integrated discrimination improvements (IDIs) were used to evaluate the predictive ability of Neu5Ac on the prognosis of p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of neuraminic acid and a neuraminidase inhibitor in chronic heart failure, belongs to the field of diagnosis, prevention and treatment of cardiovascular diseases, discloses a novel biomarker-neuraminic acid, and proves that neuraminic acid plays a role in diagnosis, prognosis biomarkers and risk stratification in the chronic heart failure and a role in preventing, relieving and / or improving the chronic heart failure as a drug target. Therefore, detection of the level of the neuraminic acid by the kit can be used for predicting and assisting in the diagnosisof the chronic heart failure or evaluating the prognosis of the chronic heart failure, and the level of the neuraminic acid is controlled through drugs so as to carry out intensive diagnosis and follow-up treatment on diseases, a favorable course of disease is obtained, and the clinical application value is huge.

Description

technical field [0001] The invention discloses the application of neuraminic acid and neuraminidase inhibitors in chronic heart failure, and specifically relates to the application of neuraminic acid and neuraminidase inhibitors in the diagnosis and prognosis evaluation of chronic heart failure, belonging to the field of heart failure. The field of diagnosis, prevention and treatment of vascular diseases. Background technique [0002] Chronic heart failure is a clinical syndrome in the development of different cardiovascular diseases to the end stage, due to initial myocardial injury of any cause (such as myocardial infarction, cardiomyopathy, hemodynamic overload, inflammation, etc.), causing myocardial structural And functional changes, finally lead to hypoventricular pumping and (or) filling function, its poor prognosis, high mortality, is one of the most important causes of threats to human health and lead to increased medical burden. At present, the treatment of chroni...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/53A61K31/215A61P9/04
Inventor 汪道文倪黎李陈泽
Owner TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com